The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer.
Authors
Fayers, P MRustin, G
Wood, R
Nelstrop, A
Leonard, R C F
Wilkinson, Peter M
Cruickshank, D
McAllister, E J
Redman, C W E
Parker, D
Scott, I V
Slevin, M L
Roulston, J E
Affiliation
MRC Cancer Trials Office, Cambridge CB2 2BB, Dept. of Medical Oncology, Charing Cross Hospital, London W6 8RF, Dept. of Oncology, Western General Hospital, Edinburgh EH4 2XU, Dept. of Oncology, Christie Hospital, Manchester M20 9BX, Dept. Obstet. & Gynaecol, Aberdeen Maternity Hospital, Aberdeen AB9 2ZA, Dept. of Biochemistry and Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, Dept. Obstetrics and Gynaecol, North Staffordshire Royal Infirmary, Stoke-on-Trent ST4 7LN, Clinical Oncology Unit, Bradford Royal Infirmary, Bradford BD9 6RJ, Dept. Obstetrics and Gynaecology, Derby City Hospital, Derby DE3 3NE, Dept. of Oncology, Homerton Hospital, London E9 6SR, Department of Clinical Biochemistry, Royal Infirmary, Edinburgh EH3 9YW, UK.Issue Date
1993-09
Metadata
Show full item recordAbstract
A number of studies have suggested that serum CA 125 levels may be an important prognostic factor for survival of patients with ovarian carcinoma. We investigated, in a large group of patients from 11 UK centers, which combination of CA 125 measurements provided the best prognostic index, and whether the predictive power could be improved by the addition of other factors. Analysis of the data from 248 patients showed that the absolute value of the third CA 125 sample was the single most important factor for predicting progression at 12 months, with the addition of residual bulk only slightly improving the predictive power. Seventy-four patients had CA 125> 70, and of these 57% were correctly predicted to progress or die within 12 months, but 43% remained alive and progression free. The best predictor for progression produced a false positive rate of 19%. We therefore conclude that prognostic information based upon CA 125 measurements up to the start of the third course of initial chemotherapy is not accurate enough to be used to manage individual patients.Citation
The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. 1993, 3 (5):285-292 Int. J. Gynecol. CancerJournal
International Journal of Gynecological CancerDOI
10.1046/j.1525-1438.1993.03050285.xPubMed ID
11578359Type
ArticleLanguage
nullISSN
1525-1438ae974a485f413a2113503eed53cd6c53
10.1046/j.1525-1438.1993.03050285.x
Scopus Count
Collections
Related articles
- The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
- Authors: Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR
- Issue date: 2004 Apr
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
- Authors: Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R
- Issue date: 2022 Sep 26
- Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
- Authors: Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Kalsi JK, Singh N, Dawnay A, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Parmar M, Jacobs IJ, UKCTOCS team
- Issue date: 2025 May
- Prognostic value of CA 125 in advanced ovarian cancer.
- Authors: Mogensen O
- Issue date: 1992 Mar
- Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
- Authors: AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
- Issue date: 2024 Feb